HC Wainwright Reaffirms “Buy” Rating for Collegium Pharmaceutical (COLL)

Share on StockTwits

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Monday, September 17th.

COLL has been the subject of several other reports. BidaskClub upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Thursday, June 21st. Cantor Fitzgerald restated a “buy” rating and set a $40.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, June 20th. ValuEngine raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 12th. Finally, Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, August 8th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $31.71.

NASDAQ:COLL traded down $0.07 during trading hours on Monday, reaching $16.95. 311,040 shares of the company were exchanged, compared to its average volume of 527,767. The company has a debt-to-equity ratio of 3.94, a quick ratio of 0.78 and a current ratio of 0.82. The stock has a market capitalization of $489.69 million, a PE ratio of -6.86 and a beta of 0.43. Collegium Pharmaceutical has a twelve month low of $9.01 and a twelve month high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.02. The company had revenue of $73.10 million during the quarter, compared to analysts’ expectations of $72.21 million. Collegium Pharmaceutical had a negative net margin of 39.10% and a negative return on equity of 61.82%. The firm’s quarterly revenue was up 1930.6% compared to the same quarter last year. Research analysts forecast that Collegium Pharmaceutical will post -1.49 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of COLL. Atria Investments LLC lifted its stake in Collegium Pharmaceutical by 81.3% in the third quarter. Atria Investments LLC now owns 15,307 shares of the specialty pharmaceutical company’s stock worth $226,000 after acquiring an additional 6,866 shares during the last quarter. United Services Automobile Association lifted its stake in Collegium Pharmaceutical by 179.9% in the second quarter. United Services Automobile Association now owns 132,805 shares of the specialty pharmaceutical company’s stock worth $3,167,000 after acquiring an additional 85,364 shares during the last quarter. Northern Trust Corp lifted its stake in Collegium Pharmaceutical by 78.5% in the second quarter. Northern Trust Corp now owns 526,499 shares of the specialty pharmaceutical company’s stock worth $12,557,000 after acquiring an additional 231,463 shares during the last quarter. Castleark Management LLC lifted its stake in Collegium Pharmaceutical by 31.9% in the second quarter. Castleark Management LLC now owns 292,878 shares of the specialty pharmaceutical company’s stock worth $6,985,000 after acquiring an additional 70,820 shares during the last quarter. Finally, Granahan Investment Management Inc. MA lifted its stake in Collegium Pharmaceutical by 192.3% in the second quarter. Granahan Investment Management Inc. MA now owns 127,460 shares of the specialty pharmaceutical company’s stock worth $3,040,000 after acquiring an additional 83,860 shares during the last quarter. 93.57% of the stock is owned by institutional investors and hedge funds.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Read More: What are the Benefits of Index Funds?

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply